Art

J-GLOBAL ID：202002244778784826   Reference number：20A1987651

Outcomes of Clinical Pharmacy Research Aimed at Avoiding or Reducing Cancer Chemotherapy-induced Adverse Reaction

がん化学療法に伴う有害反応の回避あるいは軽減を目的とした臨床薬学的研究の取り組みと臨床アウトカム

Author (4)： KAWAZOE HITOSHI (慶応大 薬 医療薬学・社会連携セ) ,  KAWAZOE HITOSHI (慶応大 大学院薬学研究科) ,  NAKAMURA TOMONORI (慶応大 薬 医療薬学・社会連携セ) ,  NAKAMURA TOMONORI (慶応大 大学院薬学研究科)
Material： 医療薬学  (Japanese Journal of Pharmaceutical Health Care and Sciences)
Volume： 46  Issue： 9  Page： 467-480  Publication year： Sep. 10, 2020 
JST Material Number： Y0888A  ISSN： 1346-342X  CODEN： IYRAA3  Document type： Article
Article type： 文献レビュー  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： *drug therapy ,...
Semi thesaurus term： *CINV ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A1987651&from=J-GLOBAL&jstjournalNo=Y0888A") }}

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Substance index (9)： Aprepitant ,  Anthracycline ,  Irinotecan ,  Epirubicin ,  Olanzapine ,  Granisetron ,  Gemcitabine ,  Dexamethasone ,  Palonosetron

Reference (55)：

• 1)Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 2017, 390, 2461-2471.
• 2)Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators, Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer, N Engl J Med, 2018, 379, 2108-2121.
• 3)Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators, Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med, 2018, 378, 2078-2092.
• 4)Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD, Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, N Engl J Med, 2015, 373, 23-34.
• 5)Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J, Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment, J Clin Oncol, 2006, 24, 4472-4478.

Terms in the title (6)： がん化学療法 ,  有害反応 ,  回避 ,  臨床薬学 ,  研究 ,  臨床アウトカム